Back to top

Analyst Blog

We maintain our long-term Neutral recommendation on Omnicell Inc. (OMCL - Analyst Report) following mixed quarterly results for the first quarter of 2013.

Why the Reiteration?

On May 2, Omnicell’s first-quarter net operating earnings of 14 cents per share missed the Zacks Consensus Estimate by a nickel. Results nevertheless improved 7.7% year over year.

Revenues in the quarter jumped 35.8% year over year to $87.1 million. Despite the considerable improvement, top-line marginally missed the Zacks Consensus Estimate of $88 million. Margin pressure due to escalating costs was another headwind for the company.

We also note that constrained hospital spending might hamper Omnicell’s market penetration in the U.S. Tough competitive landscape also remains an overhang.

However, Omnciell serves a niche industry and stands to gain from its three-pronged strategy of domestic expansion, selective acquisitions and targeted international expansion. The company’s foray into the highly profitable and underpenetrated non-acute care market with the MTS acquisition is yielding positive results.

The recent contract wins are also encouraging. Given the substantial demand in the overseas market and the low penetration rate, international contract wins are likely to accelerate growth for Omnicell.  

We believe that geographic expansion into lucrative markets such as Middle East and China should accelerate growth. Also worth mentioning in this context is Omnicell’s strong business trend in U.K. in the reported quarter.

In light of these facts, it seems like Omnicell is likely to trend higher as it has been taking a number of strategic steps to align its assets while expanding its footprint worldwide. Estimates for the ongoing year are also on the rise. As a result, the Zacks Consensus Estimate for 2013 shot up 29.2% over the last 30 days to 84 cents. This reflects estimated growth of 40% year over year.

The stock carries a Zacks Rank #2 (Buy). Other stocks in the industry carrying a Zacks Rank #2 are Merge Healthcare Incorporated (MRGE - Analyst Report), CONMED Corporation (CNMD - Analyst Report) and The Cooper Companies Inc. (COO - Analyst Report).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%